Early drug discovery typically identifies what?

• A. A single molecule ready for human testing.
• B. A promising group of lead molecules that appear to interact with the target in a desirable way that should undergo lead optimizing.
• C. A complete drug candidate with patent protection.
• D. The final dosage form.

Answer: (B)

In early drug discovery, the goal is to generate and spot several starting points—lead-like molecules—that show desirable interaction with the biological target. You don’t end up with a single molecule ready for humans yet; instead you identify a promising group of lead compounds and move them into lead optimization, where their potency, selectivity, and drug-like properties are improved through iterative chemistry and testing. This sets the stage for selecting a clinical candidate later, along with further preclinical work and formulation decisions.

The other options fit later stages. A single molecule ready for human testing is typically the result after optimization and preclinical validation. A complete drug candidate with patent protection reflects regulatory and intellectual property milestones, not early discovery content. The final dosage form comes after extensive formulation and development work, not during the initial discovery phase.